A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.
Preliminary research presented at the 2021 ASCO Annual Meeting suggests that use of a bacterial product might improve response to checkpoint inhibitor therapy in patients with metastatic renal cell carcinoma.
Patients who receive lenvatinib plus pembrolizumab for advanced renal cell carcinoma report similar or better health-related quality of life than those who receive sunitinib, show data from the phase 3 CLEAR trial.
The combination of telaglenastat and cabozantinib offers no extra benefit over cabozantinib alone in the second- or third-line treatment of advanced clear cell renal cell carcinoma, suggest phase 2 trial results.